FIELD: medicine. SUBSTANCE: method involves RNA-ase L activity assay in extract of mononuclear cells of patient peripheral blood by determination of cleavage products of 28S-RNA and 18S-RNA and bioactive 21-51-oligomers. If activated RNA-ase L is not detected then ampligen ® is administrated at the dose 50-250 mg at rate which is sufficient for attainment of g3 RNA 0.01-1 mcg/ml in blood. EFFECT: increased effectiveness of recovery. 3 tbl
Authors
Dates
1994-10-30—Published
1988-11-04—Filed